Scrip Podcasts

Norstella
Norstella
  • 0.0 (0)
  • Business
  • Weekly

Scrip delivers expert-driven audio insight on biopharma — from R&D, commercial strategy and deal activity to coverage of major industry events. Every Monday, Ian Haydock presents Quick Listen: Five Must-Know Things, a weekly roundup of top industry stories. Joseph Haas hosts a quarterly deep-dive into dealmaking with guests from leading companies, law firms and investment firms. Visit https://insights.citeline.com/scrip to sign up. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.

  1. 2d ago

    Rethinking Risk: Why Early Evidence Strategy Matters for Emerging Biotechs

    For emerging biotech companies, development success is often measured by clinical milestones, safety, and efficacy. However, demonstrating an asset’s value extends beyond regulatory approval. Understanding patient needs and treatment experiences, as well as evolving stakeholder expectations, early in development plays an important role in shaping a more informed evidence strategy. In this podcast, Ashwin Rai, Director of Data Science and Advanced Analytics, and Gale Harding, Senior Research Leader, from the PPD clinical research business of Thermo Fisher Scientific, discuss how integrating real-world data and patient-centered insights earlier in development can help developers address evidence gaps, inform critical decisions, and build a stronger foundation for demonstrating treatment value. What the Podcast Explores • Why evidence planning should begin early in asset development, rather than closer to commercialization • How real-world data can help identify unmet needs, understand patient journeys, and inform development decisions, and why more data doesn’t necessarily mean better data • The importance of capturing patient experiences and outcomes beyond traditional clinical endpoints • How patient-centered research can help address evidence gaps and strengthen an asset’s value story • Why evidence strategies must evolve alongside changing stakeholder expectations and development priorities

    Rethinking Risk: Why Early Evidence Strategy Matters for Emerging Biotechs

  2. 3d ago

    Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast)

    本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月30日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括：美国《COINS法案》的影响；葛兰素史克（GSK）在肿瘤领域的业务转型；礼来（Lilly）在KRAS领域的推进；ris-rez为骨肉瘤治疗带来新希望；以及Genmab最新III期临床试验的胜利。 Story links here. 向听众们简要更新一下：Scrip 现在已在 Spotify 和 Apple Podcasts 上开设了专属播客频道。 Scrip YouTube Podcasts: https://www.youtube.com/@scrip-commercial/podcasts Feedback: podcasts@norstella.com

  3. 3d ago

    Scrip's Five Must-Know Things: US COINS Impact, GSK's Oncology Turnaround, Lilly's KRAS Push

    Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 30, 2026. This time—US COINS Act impact; GSK’s oncology turnaround; Lilly’s KRAS push; ris-rez gives new hope in osteosarcoma; and Genmab’s latest Phase III win.  Story links here. This and all our other podcasts are available on the Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Scrip YouTube Podcasts: https://www.youtube.com/@scrip-commercial/podcasts Any comments? podcasts@norstella.com

    Scrip's Five Must-Know Things: US COINS Impact, GSK's Oncology Turnaround, Lilly's KRAS Push

  4. Oct 28

    Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.26, 2026

    本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月23日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括：欧洲肿瘤内科学会（ESMO）会议的关键预期；新一代抗体药物偶联物；冉冉升起的中盘股新星；葛兰素史克（GSK）新型乙肝药物的上市；以及私营企业的重大融资动态。 Story links here.  向听众们简要更新一下：Scrip 现在已在 Spotify 和 Apple Podcasts 上开设了专属播客频道。 Scrip YouTube Podcasts: https://www.youtube.com/@scrip-commercial/podcasts Pink Sheet YouTube Podcasts: https://www.youtube.com/@pinkSheet-regulatory-n/podcasts Feedback: podcasts@norstella.com

  5. Oct 28

    Scrip's Five Must-Know Things: Key ESMO Readouts, Next-Gen ADCs And Mid-Cap Winners

    Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 23, 2026. This time—key expectations from ESMO meeting; next-generation antibody-drug conjugates; rising mid-cap stars; GSK's novel hepatitis B launch; and significant private company financings. Story links here. This and all our other podcasts are available on the Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Scrip YouTube Podcasts: https://www.youtube.com/@scrip-commercial/podcasts Pink Sheet YouTube Podcasts: https://www.youtube.com/@pinkSheet-regulatory-n/podcasts Any comments? podcasts@norstella.com

    Scrip's Five Must-Know Things: Key ESMO Readouts, Next-Gen ADCs And Mid-Cap Winners

  6. Oct 22

    Scrip Awards Podcast – Parabilis CEO Mathai Mammen Interview

    Ahead of the awards presentation on Dec 2, the Scrip Awards podcast speaks to Mathai Mammen, CEO of Parabilis, one of the shortlisted companies for Biotech of The Year.

    Scrip Awards Podcast – Parabilis CEO Mathai Mammen Interview

  7. Oct 19

    Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Oct.19, 2026

    本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月16日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本周内容包括：Tremfya从Stelara的余烬中崛起；辉瑞将成熟品牌作为试验田；中国科研力量在第三季度交易中大放异彩；Argenx在自身免疫领域取得进展与遭遇挫折；日本力图重振生物制药竞争力。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-IZOIOAJVX5ERZMYRIYPGPLUVFA/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Feedback: podcasts@norstella.com

  8. Oct 19

    Scrip's Five Must-Know Things - Oct. 19, 2026

    Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended Oct. 16, 2026. This time—Tremfya rises from Stelara’s ashes; Pfizer uses mature brands as testbeds; Chinese science shines in Q3 deals; autoimmune win and setback for Argenx; and Japan looks to restore biopharma competitiveness. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-IZOIOAJVX5ERZMYRIYPGPLUVFA/ This and all our other podcasts are available on the Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Any comments? podcasts@norstella.com

    Scrip's Five Must-Know Things - Oct. 19, 2026
See All (47)

Trailer

About

Scrip delivers expert-driven audio insight on biopharma — from R&D, commercial strategy and deal activity to coverage of major industry events. Every Monday, Ian Haydock presents Quick Listen: Five Must-Know Things, a weekly roundup of top industry stories. Joseph Haas hosts a quarterly deep-dive into dealmaking with guests from leading companies, law firms and investment firms. Visit https://insights.citeline.com/scrip to sign up. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.

Information

  • Channel
    Norstella
  • Creator
    Norstella
  • Years Active
    2026
  • Episodes
    47
  • Copyright
    © All rights reserved
  • Show Website
    Scrip Podcasts

More From Norstella

You Might Also Like